CSL FINANCIAL STATEMENTS

CSL Ltd — balance sheet, income statement and cash flow trends

CSLCSL Ltd

🇦🇺 Australia · AU · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q2 2025 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue15.7 B $+9.9%

Gross Profit7.6 B $+10.3%

Operating Income4 B $+15.2%

EBITDA5.1 B $+12.9%

Net Income1.4 B $-62.2%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CSL	4.8%	48.6%	32.8%	9.2%
ROIV	-67.7%	84.4%	-3,162.6%	-3,629.2%
MRNA	-29.1%	-13.9%	-129.7%	-143.6%
RPRX	7.8%	100.0%	69.6%	33.9%
INCY	21.5%	92.5%	34.9%	26.7%
INSM	115.1%	81.6%	-131.9%	-144.4%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CSL	4.8%	48.6%	32.8%	9.2%
SIG	45.7%	5.5%	0.9%	-0.3%
RMD	10.5%	61.2%	39.1%	27.4%
PME	30.3%	78.4%	78.4%	97.6%
FPH	4.8%	64.2%	34.9%	20.0%
SHL	11.4%	29.6%	17.3%	5.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q2 2025

Equity18.7 B $52%
Current Liabilities4.6 B $13%
Long-term Liabilities12.8 B $36%

Key Figures

YoY change

Total Assets37.9 B $+1.9%

Total Liabilities17.5 B $-3.6%

Total Equity18.7 B $+8.9%

Cash & ST Investments1.1 B $+12.9%

Total Debt12.6 B $+4.1%

Net Debt11.4 B $+3.3%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CSL	2.57	67.4%	2.22	49.2%
ROIV	18.37	2.4%	16.03	79.0%
MRNA	2.41	17.5%	1.35	64.5%
RPRX	2.66	130.0%	4.91	34.8%
INCY	3.68	0.6%	-2.13	75.7%
INSM	4.47	106.2%	0.44	34.0%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CSL	2.57	67.4%	2.22	49.2%
SIG	1.59	15.8%	2.82	45.8%
RMD	3.01	13.0%	-0.38	73.9%
PME	6.22	1.1%	-1.16	72.8%
FPH	2.31	6.9%	-0.39	74.1%
SHL	1.01	85.8%	3.78	50.3%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q2 2025 · TTM

Key Figures

YoY change

Operating Cash Flow3.8 B $+61.4%

Capital Expenditures584.7 M $-52.3%

Free Cash Flow3.2 B $+187.7%

Dividends Paid-1.5 B $-243.0%

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CSL	24.0%	20.3%	3.7%	261.5%
ROIV	-9,084.1%	-9,183.5%	218.9%	250.3%
MRNA	-64.9%	-71.1%	6.2%	45.2%
RPRX	108.8%	108.8%	0.0%	320.7%
INCY	28.3%	27.1%	1.2%	105.9%
INSM	-109.3%	-116.1%	6.8%	75.7%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CSL	24.0%	20.3%	3.7%	261.5%
SIG	-6.5%	-6.7%	0.2%	2,280.0%
RMD	34.2%	31.7%	2.5%	124.8%
PME	56.5%	56.3%	0.2%	57.9%
FPH	28.4%	21.0%	7.4%	141.7%
SHL	13.1%	8.3%	4.7%	251.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CSL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.